All In Biotech

Drug Trial Radar · NCT05991388

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

May 2, 2024

Primary completion

May 1, 2031

Study completion May 1, 2033

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK; Fight Kids Cancer; Regeneron Pharmaceuticals; ADC Therapeutics S.A.
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. Examples of B-NHL are Burkitt Lymphoma and Diffuse Large B Cell Lymphoma, which may be other names used to describe this type of cancer. It is very difficult to cure relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and only cure around 30 in every 100 children treated. It is very important that investigators quickly find better medicines for these children and young people. The Glo-BNHL trial will include three groups of children and young people, each given a new medicine (either alone or with chemotherapy). The investigators are looking to make sure the new medicines are safe and that they work to treat the cancer. If the medicine in one group does not work for a child in the trial, then they may be able to join a different group to have another new medicine. Experts from around the world will carefully pick the medicines most likely to be helpful to be part of the trial. If one of the new medicines seems not to be working as well as hoped then the investigators will take it out of the trial as soon as possible. This will let other new medicines be added to the trial and tested. If a medicine does seem to be working well, then it will continue in the trial to make sure it really is the most useful medicine available. Children from around the world will be invited to take part in the trial. The investigators will then check on them for at least two years after they finish the trial treatment to look for possible side effects of the new medicine.

Conditions

  • B-cell Non Hodgkin Lymphoma

Interventions

  • OdronextamabDrug

    CD20xCD3 bispecific antibody

  • Loncastuximab tesirineDrug

    CD-19-directed antibody-drug conjugate

  • RituximabDrug

    Modified R-ICE chemotherapy

  • IfosfamideDrug

    Modified R-ICE chemotherapy

  • CarboplatinDrug

    Modified R-ICE chemotherapy

  • EtoposideDrug

    Modified R-ICE chemotherapy

  • Etoposide PhosphateDrug

    Modified R-ICE (Treatment Arm II)

  • DexamethasoneDrug

    Modified R-ICE chemotherapy

  • CAR T-cells (TBC)Biological

    Modified R-ICE chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Arm I: BsAb: Occurrence of an objective response (OR)Time frame: At the end of week 12 of treatment
  2. Treatment Arm II: ADC with standard chemotherapy: Occurrence of CRTime frame: At the end of Cycle 2 and Cycle 3 of treatment (each cycle is 28 days)

Locations

11 sites in 7 countries. Site status is shown where the registry gives one.

  • The Children's Hospital at Westmead

    Sydney, New South Wales, Australia · Not yet recruiting

  • Queensland Children's Hospital

    Brisbane, Queensland, Australia · Not yet recruiting

  • Perth Children's Hospital

    Perth, Washington, Australia · Recruiting

  • St. Anna Children's Hospital

    Vienna, Austria · Recruiting

  • UZ Leuven

    Leuven, Belgium · Not yet recruiting

  • Princess Máxima Centre for Pediatric Oncology

    Utrecht, Netherlands · Recruiting

  • Starship Children's Hospital

    Auckland, New Zealand · Not yet recruiting

  • Sahlgrenska University Hospital

    Gothenburg, Sweden · Not yet recruiting

  • Birmingham Children's Hospital

    Birmingham, United Kingdom · Recruiting

  • Bristol Royal Hospital for Children

    Bristol, United Kingdom · Recruiting

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.